# Mounjaro (Tirzepatide) - Patient Demographics & Persona Research

## Overview

This document compiles research data on Mounjaro/tirzepatide patient demographics and user personas for GLP-1 receptor agonist medications.

---

## Key Demographic Insights

### Gender Distribution
| Region | Female % | Male % |
|--------|----------|--------|
| UK (Mounjaro) | 77.6% | 22.4% |
| Global (GLP-1s) | ~65% | ~35% |

**Note:** Higher female usage may be influenced by:
- Societal pressures on women regarding body weight
- Greater openness to medical interventions for weight loss

---

### Age Distribution

| Age Group | UK Mounjaro Users |
|-----------|-------------------|
| 20-29 | Low usage |
| 30-39 | Significant portion |
| 40-59 | **Over 50% of users** |
| 60+ | Lower percentage |

- **Mean age:** 50.2 years
- **Median age:** 44 years
- Women in their 30s and those over 50 are significant users

### US GLP-1 Usage by Age
| Age Group | % of Obesity Population | % of GLP-1 Users |
|-----------|------------------------|------------------|
| 45-54 | 16.1% | 24.3% |

---

### Socioeconomic Factors

**Income Disparity:**
- Patients earning >$250,000/year are **72% more likely** to take GLP-1s than those earning ≤$50,000
- High costs create barriers for lower-income individuals
- In UK, ~10x more people purchase Mounjaro privately vs. NHS due to stricter eligibility

---

### Racial/Ethnic Disparities (US Data)

| Ethnicity | GLP-1 Usage Rate |
|-----------|-----------------|
| Non-Hispanic White | 5.1% |
| Non-Hispanic Black | 4.1% |
| Native American | 4.0% |
| Hispanic | 3.7% |

**Note:** Black, Asian, and Hispanic patients are less likely to receive GLP-1 treatment compared to White patients, despite higher obesity prevalence.

---

## Patient Personas

### Persona 1: "Weight Loss Motivated"
**Demographics:** Women 30-55, middle-to-high income
**Characteristics:**
- Primarily driven by desire to lose weight
- Willing to tolerate side effects (nausea) for weight loss results
- Appreciates improvements in physical functioning and QoL
- Active on social media, may have heard about medication through online communities

### Persona 2: "Comorbidity-Conscious"
**Demographics:** Adults 45-65, often with T2D diagnosis
**Characteristics:**
- Keenly aware of health risks (cardiovascular disease, kidney issues)
- Motivated by broader health benefits beyond weight loss
- Values cardiovascular and renal protection
- More likely to follow prescribed regimens consistently

### Persona 3: "Treatment-Weary"
**Demographics:** Adults who have tried multiple therapies
**Characteristics:**
- Previous attempts at weight management with limited success
- May have tried metformin, other diabetes medications
- Seeking more effective options
- Appreciates simpler dosing regimens (once weekly)
- Risk of discontinuation if side effects are bothersome

### Persona 4: "Cost-Sensitive/Access-Challenged"
**Demographics:** Lower-to-middle income, may lack comprehensive insurance
**Characteristics:**
- Financial burden is significant hurdle
- Limited insurance coverage affects access
- May struggle with adherence due to cost
- May use savings programs when available

### Persona 5: "Information-Seeking/Self-Directed"
**Demographics:** Tech-savvy adults, various ages
**Characteristics:**
- Actively researches treatments online
- May initiate conversations with HCPs about GLP-1s
- Influenced by social media and word-of-mouth
- May deviate from dosing schedules
- Values autonomy in healthcare decisions

---

## Typical Patient Profile for Mounjaro

### Primary Indications
1. **Type 2 Diabetes Mellitus** - Adults requiring improved glycemic control
2. **Chronic Weight Management** - Adults with:
   - BMI ≥ 35 kg/m²
   - OR BMI ≥ 27 with weight-related comorbidities

### Common Characteristics
- Adults who can adhere to once-weekly injectable regimen
- Patients with specific comorbidities that need evaluation
- Individuals for whom weight gain is harder to manage with age
- Experiencing health issues linked to weight

### Contraindications to Consider
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis

---

## UK Market Share

| Medication | UK GLP-1 Market Share |
|------------|----------------------|
| Mounjaro | ~79% |
| Wegovy | ~20% |
| Other | ~1% |

**Reason for dominance:** Dual action on both GLP-1 and GIP receptors leads to greater weight loss compared to GLP-1-only medications.

---

## Sources

1. Real Chemistry GLP-1 Patient Profile Report
2. Click2Pharmacy UK User Statistics
3. NIH/PubMed Patient Behavior Studies
4. FDA Clinical Trial Demographics
5. Multiple peer-reviewed publications on GLP-1 utilization patterns
